CRBP

INSIDER BUYINSIDER SELL

Corbus Pharmaceuticals Holdings, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

3.9d↑+10.7%

as of 2026-09-30

News Summary

Positive

Corbus achieved two major clinical catalysts since June 30, 2026: FDA clearance for the pivotal TEMPO-1 registrational trial of CRB-701 in oropharyngeal cancer and positive Phase 1b CANYON-1 data for CRB-913 obesity candidate showing 5% weight loss with favorable GI tolerability. However, the company posted a significant earnings miss ($1.81 loss/share vs. $1.26 consensus) and stock rallied 342% YTD on pipeline enthusiasm rather than financial performance, suggesting valuation risk.

Red flags

•Q2 2026 EPS miss of 43.7% versus consensus estimate ($1.81 actual vs. $1.26 expected)
•Both lead programs are early-stage; CRB-701 is just entering pivotal trial enrollment and CRB-913 has only Phase 1b data
•Extreme 342% YTD stock rally creates elevated valuation risk with limited near-term revenue visibility
•Market cap of ~$124M is small and may indicate limited institutional conviction beyond clinical catalysts

Insider Activity

Name	Title	Type	Shares	Price	Value	Filed	Src
Ben Yong	—	SELL	2K	$7.84	$0.02M	2026-09-14	↗
Saxena Nishant C	Chief Business Officer	BUY	3K	$9.63	$0.03M	2026-08-11	↗
Cohen Yuval	Chief Executive Officer	SELL	17K	$10.08	$0.17M	2026-08-07	↗
Moran Sean F.	Chief Financial Officer	SELL	12K	$10.08	$0.12M	2026-08-07	↗

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Citadel Advisors	SC 13G/A	—	1.1%	-48.3% vs SPY -47.8% abs	2026-08-14	↗